ctDNA

You have access
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu and Peng Yuan

Cancer Biology & Medicine August 2021, 18 (3) 849-859; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0463
You have access
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
Anjie Zhu, Peng Yuan, Nanlin Hu, Mingzhou Li, Wenmiao Wang, Xue Wang, Jian Yue, Jiayu Wang, Yang Luo, Fei Ma, Pin Zhang, Qing Li, Binghe Xu, Shanbo Cao, Giuseppe Lippi, Yoichi Naito, Mohammed A. Osman, Gustavo N. Marta, Gianluca Franceschini and Armando Orlandi

Cancer Biology & Medicine August 2021, 18 (3) 875-887; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0418
You have access
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
Wenxiao Jia, Qianqian Gao, Anqin Han, Hui Zhu and Jinming Yu

Cancer Biology & Medicine November 2019, 16 (4) 655-670; DOI: https://doi.org/10.20892/j.issn.2095-3941.2019.0144

Main menu